Forced mid-expiratory flow (i.e., isoFEF₂₅₋₇₅) may increase with a short-acting β₂-agonist in nonasthmatic children without bronchodilator responsiveness. This could also increase estimated ventilatory capacity along mid-expiration (V̇Ecap₂₅₋₇₅), especially in vulnerable children with obesity who exhibit altered breathing mechanics. We estimated V̇Ecap₂₅₋₇₅ pre- and post-albuterol treatment in 8−12yo children without (n = 28) and with (n = 46) obesity. A two-way ANOVA was performed to determine effects of an inhaled bronchodilator (pre-post) and obesity (group) on isoFEF₂₅₋₇₅ and V̇Ecap₂₅₋₇₅. There was no group by bronchodilator interaction or main group effect on outcome variables. However, a significant main effect of the bronchodilator was detected in spirometry parameters, including a substantial increase in isoFEF₂₅₋₇₅ (17.1 ± 18.0 %) and only a slight (non-clinical) but significant increase in FEV₁ (2.4 ± 4.3 %). V̇Ecap₂₅₋₇₅ significantly increased with albuterol (+11.7 ± 10.6 L/min; +15.8 ± 13.9 %). These findings imply potentially important increases in ventilatory reserve with a bronchodilator in nonasthmatic children without and with obesity, which could potentially influence respiratory function at rest and during exercise.

在没有支气管扩张剂反应的非哮喘儿童中，使用短效 β ₂激动剂可能会增加强制呼气中流量（即 isoFEF _{25-75 ）。}这也可以增加呼气中期的估计通气能力（V̇Ecap _25-75），特别是在表现出呼吸力学改变的肥胖易感儿童中。我们在没有（n = 28）和（n = 46）肥胖的 8-12 岁儿童中估计了 V̇Ecap _{25-75前和后沙丁胺醇治疗。}进行双向 ANOVA 以确定吸入支气管扩张剂（事前）和肥胖（组）对 isoFEF _25-75和 V̇Ecap _{25-75的影响}. 支气管扩张剂相互作用或主要组对结果变量的影响没有分组。然而，在肺活量参数中检测到支气管扩张剂的显着主要影响，包括 isoFEF _{25-75的显着增加（17.1 ± 18.0 %）和 FEV 1}仅轻微（非临床）但显着增加（2.4 ± 4.3 % ） ）。V̇Ecap ₂₅₋₇₅随沙丁胺醇显着增加（+11.7 ± 10.6 L/min；+15.8 ± 13.9 %）。这些发现表明，在没有和有肥胖症的非哮喘儿童中使用支气管扩张剂可能会显着增加通气储备，这可能会影响休息和运动期间的呼吸功能。